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been identified as good markers of myocardial 
hemodynamic stress, and their clinical utility is 
well established. BNP and NT‑proBNP are clinical‑
ly validated and significantly improve diagnostic 
accuracy for heart failure and provide prognostic 
information for risk stratification. The greatest 
diagnostic utility provided by the measurement 
of BNPs is high accuracy in excluding the diagno‑
sis of heart failure in a patient presenting with 
dyspnea (clinical sensitivity and negative predic‑
tive value for BNP and NT‑proBNP is higher than 
90%, but correction for age, sex, and body mass 
index is necessary for cutoff). However, they are 
not useful for a differential diagnosis of heart fail‑
ure due to their relatively low specificity. The use 
of either BNP or NT‑proBNP to diagnose decom‑
pensated heart failure in dyspnea patients with 
concomitant moderate renal disease (estimated 
glomerular filtration rate, 30–59 ml/min/1.73 m2) 
is generally clinically accepted.
NT‑proBNP is a  biomarker that results in 
the most added prognostic value on top of tradi‑
tional risk factors for cardiovascular and all‑cause 
mortality in incident hemodialysis (HD) pa‑
tients.3 Serum NT‑proBNP concentrations are 
elevated in nearly all HD patients in comparison 
with the general population, and the concentra‑
tion depends on the time of measurement (be‑
fore and after an HD session). The extent of this 
increase is associated with cardiovascular mor‑
bidity and mortality. Plasma NT‑proBNP levels 
are elevated in approximately 100% of asymp‑
tomatic patients on chronic HD. This increase 
is caused by a high prevalence of structural and 
functional abnormalities in the left ventricle in 
dialysis patients.4,5
The measurement of NT‑proBNP levels in pa‑
tients with end‑stage renal disease (ESRD) re‑
ceiving HD or peritoneal dialysis is clinically im‑
portant as this marker has a significant prog‑
nostic value. There have been numerous stud‑
ies showing the role of NT‑proBNP in predicting 
all‑cause and cardiovascular death independent of 
In many clinical situations, the measurement of 
biochemical markers can be potentially used for 
diagnosis, risk assessment, prognosis, or thera‑
peutic monitoring of the patient. A biomarker is 
a parameter that is objectively measured and may 
be regarded as an indicator of normal or path‑
ological biological processes. B‑type natriuret‑
ic peptide (BNP, a biologically active form) and 
N‑terminal pro‑BNP (NT‑proBNP, a biological‑
ly inert form) are synthesized and released from 
the ventricular myocardium in the setting of vol‑
ume or pressure overload. BNP and NT‑proBNP 
are secreted at a ratio of 1:1 but NT‑proBNP has 
a longer half‑life than BNP (90–120 minutes vs 
20 minutes). In addition, it shows better analyti‑
cal characteristics, lower in‑vivo and in‑vitro deg‑
radation, higher circulating concentrations, low‑
er biological variability, and can be measured in 
EDTA or heparinized plasma and serum. 
 The  cleavage of proBNP to form BNP and 
NT‑proBNP is no longer considered a simple pro‑
cess. It is now known that multiple glycosylated 
and protelytically cleaved forms of natriuretic 
peptides are present in the circulation of healthy 
and ill individuals. O‑linked glycosylation at mul‑
tiple amino acid residues within the N‑termi‑
nal and central portions of proBNP gives differ‑
ent glycosylated forms of NT‑proBNP. Commer‑
cially available NT‑proBNP immunoassays show 
little cross‑reactivity with glycosylated proBNP 
but notable cross‑reactivity with deglycosylated 
proBNP. Thus, NT‑proBNP assays measure only 
a small fraction of the circulating NT‑proBNP in 
most patients.1 The measurement of a single na‑
triuretic peptide may not be sufficient to fully un‑
derstand the diagnostic and prognostic value of 
these biomarkers in a broad array of patients with 
varying degrees of acute and chronic heart failure.
BNP has a cardioprotective effect, improving 
myocardial relaxation and counteracting vaso‑
constriction, sodium retention, and antidiuretic 
effects of the activated renin–angiotensin–aldo‑
sterone system.2 Both BNP and NT‑proBNP have 
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interpret because they are multifactorial, and 
the serum matrix is frequently unpredictable. The 
interpretation of NT‑proBNP must take into ac‑
count intra‑ and interindividual variations both 
in healthy subjects and in those with stable chron‑
ic heart failure, as well as age (increase with age), 
sex (higher levels in women than in men), and 
body mass index (increase with body mass).
NT‑proBNP holds promise for future diagnostic 
procedures in the dialysis population not only be‑
cause of the early identification of patients at risk 
for cardiovascular complications and mortality 
but also because of the assessment of their over‑
hydration status. The lack of a single set of “nor‑
mal values” due to different clinical conditions 
leads to confusion in clinical application. Natri‑
uretic peptides should not be used on their own 
but in addition to a medical history, physical ex‑
amination, and other laboratory tests. As always, 
apart from perfect technology and sophisticated 
laboratory measurements, a careful clinical exam‑
ination is strongly recommended.
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left ventricular mass and ejection fraction in HD 
patients without a history of heart failure and in 
peritoneal dialysis patients.5,6 It was shown that 
patients with NT‑proBNP in the highest quartile 
had the highest risk of mortality and sudden car‑
diac death.7 Increased NT‑proBNP levels togeth‑
er with cardiac troponin T are strongly associat‑
ed with an adverse outcome in ESRD patients un‑
dergoing HD, and are useful tools for risk strati‑
fication in patients on chronic HD.8
Although circulating NT‑proBNP levels may 
decline after dialysis, both pre‑ and postdialysis 
NT‑proBNP levels remain a significant predictor 
of mortality independent of left ventricular mass 
and ejection fraction.9 HD patients often have as‑
ymptomatic coronary artery disease and left ven‑
tricular or diastolic dysfunction.10 Cardiac tissue 
remodeling is induced not only by ischemia but 
also by hypervolemia.
Schwermer et al.11 in the current issue of Pol 
Arch Med Wewn investigated the usefulness of 
NT‑proBNP as a hydratation marker in HD pa‑
tients along with its relation to nutritional status 
and prognosis. The authors emphasized the high 
mortality rate in HD patients due to excessive car‑
diovascular disease burden from coronary artery 
disease, left ventricular hypertrophy, and heart 
failure. It is well known that cardiac biomarkers 
are significant predictors of cardiovascular and 
all‑cause mortality in ESRD patients.
The assessment of overhydration status is very 
important in patients on HD because adequate 
body hydration reduces hypertension and the risk 
for cardiovascular complications and death.12 The 
estimation of body fluids using bioimpedance 
measurements is based on an inverse relation 
between body resistance and the total amount 
of body water and is increasingly common in 
clinical practice. With respect to a detailed as‑
sessment of body composition and nutritional 
status, an improvement in bioimpedance tech‑
nique is needed. Nowadays, NT‑proBNP is more 
frequently measured in dialysis patients; there‑
fore, the idea of using this marker as an indepen‑
dent marker of hydration is very tempting. It has 
been already suggested that NT‑proBNP may re‑
flect hydration status in dialysis patiens8 as se‑
rum NT‑proBNP levels depend on changes in flu‑
id distribution.5 More precisely, the serum level 
of NT‑proBNP represents a combination of left 
ventricular hypertrophy, systolic dysfunction, and 
volume overload.5 Nongnuch et al.13 found a sig‑
nificant correlation between NT‑proBNP levels 
and biochemical and clinical overhydration‑re‑
lated parameters, but this was not confirmed by 
Paniagua et al.14 A detailed study by Schwermer 
et al.11 showed that NT‑proBNP seems to be a val‑
id biomarker of hypervolemia. The authors sug‑
gested the measurement of this marker for the as‑
sessment of hydratation in HD units without ac‑
cess to bioimpedance methods or other objec‑
tive techniques of assessing hydradation status.
Laboratory measurements in chronic kidney 
disease‑related disorders are very difficult to 
